End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13,830 KRW | -.--% | +3.67% | -3.29% |
16/04 | Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea, | MT |
15/04 | Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea | CI |
Sales 2022 | 544B 393M 32.81B | Sales 2023 | 523B 378M 31.54B | Capitalization | 197B 142M 11.88B |
---|---|---|---|---|---|
Net income 2022 | 10.68B 7.72M 645M | Net income 2023 | -28.8B -20.82M -1.74B | EV / Sales 2022 | 0.9 x |
Net Debt 2022 | 258B 187M 15.6B | Net Debt 2023 | 280B 202M 16.89B | EV / Sales 2023 | 0.91 x |
P/E ratio 2022 |
21.6
x | P/E ratio 2023 |
-6.84
x | Employees | 937 |
Yield 2022 |
2.39% | Yield 2023 |
-
| Free-Float | 56.55% |
1 week | +3.67% | ||
Current month | -2.40% | ||
1 month | -2.40% | ||
3 months | -1.78% | ||
6 months | +18.61% | ||
Current year | -3.29% |
Managers | Title | Age | Since |
---|---|---|---|
Jeong-Yeol Jo
CEO | Chief Executive Officer | 57 | - |
Young-Jin Kim
CEO | Chief Executive Officer | 67 | 01/84/01 |
Seong-Joon Hong
DFI | Director of Finance/CFO | 59 | 21/17/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Young-Jin Kim
CEO | Chief Executive Officer | 67 | 01/84/01 |
Chul-Joon Kim
BRD | Director/Board Member | 71 | 13/09/13 |
Hyun-Ik Kim
BRD | Director/Board Member | 62 | - |
Date | Price | Change | Volume |
---|---|---|---|
30/24/30 | 13,830 | -.--% | 13,950 |
29/24/29 | 13,830 | +3.36% | 30,082 |
26/24/26 | 13,380 | -0.30% | 7,929 |
25/24/25 | 13,420 | -0.07% | 10,742 |
24/24/24 | 13,430 | +0.30% | 9,596 |
End-of-day quote Korea S.E., April 30, 2024
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.29% | 138M | |
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |
- Stock Market
- Equities
- A002390 Stock